Symbicort
Sponsors
Astrazeneca AB, AstraZeneca AB, AstraZeneca, Stanford University, Maisonneuve-Rosemont Hospital
Conditions
AsthmaAsthma, AllergicBronchiectasisBronchiolitis ObliteransCOPDCOPD PatientsChronic Obstructive Lung DiseaseCryptogenic Organizing Pneumonia
Phase 2
Phase 3
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
CompletedNCT01360021
Start: 2011-11-30End: 2012-08-31Updated: 2014-03-11
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
CompletedNCT02157935
Start: 2014-06-27End: 2016-02-08Updated: 2017-11-07
Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients
CompletedNCT03015259
Start: 2016-12-29End: 2018-02-08Updated: 2022-08-24
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
CompletedNCT03468790
Start: 2018-05-09End: 2021-03-09Updated: 2021-10-11
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressurised MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)
CompletedCTIS2023-505787-11-00
Start: 2021-04-29End: 2025-03-18Target: 678Updated: 2025-05-05
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
CompletedCTIS2023-505786-88-00
Start: 2021-04-25End: 2025-03-19Target: 441Updated: 2025-03-21
A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler® in Participants with Inadequately Controlled Asthma (VATHOS)
CompletedCTIS2024-513568-24-00
Start: 2022-03-23End: 2025-02-12Target: 160Updated: 2025-02-20
Phase 4
Unknown Phase
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
CompletedNCT00573222
Start: 2007-11-30End: 2008-05-31Updated: 2010-12-01
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler
CompletedNCT00812682
Start: 2006-09-30End: 2007-08-31Updated: 2011-01-24
Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations
CompletedNCT01218399
Start: 2009-09-30End: 2010-07-31Updated: 2017-08-18
U-LABA/ICS Effects on Exercise Performance, Formoterol
CompletedNCT06105671
Start: 2024-01-05End: 2024-07-04Updated: 2024-08-13